Abstract
We previously developed TANTIGEN, a comprehensive online database cataloging more than 1000 T cell epitopes and HLA ligands from 292 tumor antigens. In TANTIGEN 2.0, we significantly expanded coverage in both immune response targets (T cell epitopes and HLA ligands) and tumor antigens. It catalogs 4,296 antigen variants from 403 unique tumor antigens and more than 1500 T cell epitopes and HLA ligands. We also included neoantigens, a class of tumor antigens generated through mutations resulting in new amino acid sequences in tumor antigens. TANTIGEN 2.0 contains validated TCR sequences specific for cognate T cell epitopes and tumor antigen gene/mRNA/protein expression information in major human cancers extracted by Human Pathology Atlas. TANTIGEN 2.0 is a rich data resource for tumor antigens and their associated epitopes and neoepitopes. It hosts a set of tailored data analytics tools tightly integrated with the data to form meaningful analysis workflows. It is freely available at http://projects.met-hilab.org/tadb.
Highlights
Advances in instrumentation and progress in immuno-oncology are driving a revolution in cancer care
To support the development of rationally designed epitope-based cancer vaccines, we previously developed TANTIGEN, a comprehensive web-based database cataloging more than 1000 T cell epitopes and Human leukocyte antigen (HLA) ligands from 292 different tumor T cell antigens [22]
In TANTIGEN 2.0, we cataloged more than 1000 validated tumor T cell epitopes and over 500 HLA binding ligands (1,676 in total)
Summary
Advances in instrumentation and progress in immuno-oncology are driving a revolution in cancer care. TCR sequences with validated cognate antigens are essential for cell-based vaccine design. TSAs may be mutated tumor neoantigens [12], cancer-testis antigens [13], or oncofetal proteins [14]. Correct identification and cataloging of T cell antigens that aid tumor rejection will allow the development of highly effective personalized cancer vaccine immunotherapies and understand the protection mechanism.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
